{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:55:09Z","timestamp":1790902509967,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"EULAR","doi-asserted-by":"publisher","award":["CLI113"],"award-info":[{"award-number":["CLI113"]}],"id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ero.2025.05.001","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:14:51Z","timestamp":1765541691000},"page":"100017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical, biological, and radiological changes under therapy, and criteria for clinical response and remission in adult-onset Still's disease: a systematic literature review informing the development of the European Alliance of Associations for Rheumatology (EULAR) criteria for assessing disease activity"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4901-2059","authenticated-orcid":false,"given":"Charlotte","family":"Girard-Guyonvarc\u2019h","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5244-7881","authenticated-orcid":false,"given":"St\u00e9phane","family":"Mitrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3487-8551","authenticated-orcid":false,"given":"Piero","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8845-4274","authenticated-orcid":false,"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-3063","authenticated-orcid":false,"given":"Cem","family":"Gabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-7406","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Gonzalez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0670-9638","authenticated-orcid":false,"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3073-7284","authenticated-orcid":false,"given":"Tanja","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ero.2025.05.001_bib0001","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","article-title":"A comprehensive review on adult onset Still\u2019s disease","volume":"93","author":"Giacomelli","year":"2018","journal-title":"J Autoimmun"},{"issue":"10","key":"10.1016\/j.ero.2025.05.001_bib0002","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still's disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.05.001_bib0003","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12916-016-0738-8","article-title":"Adult-onset Still\u2019s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers","volume":"14","author":"Ruscitti","year":"2016","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0004","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/art.1780300209","article-title":"Adult-onset still\u2019s disease","volume":"30","author":"Cush","year":"1987","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ero.2025.05.001_bib0005","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/ard.54.7.587","article-title":"Epidemiology of adult Still\u2019s disease: estimate of the incidence by a retrospective study in west France","volume":"54","author":"Magadur-Joly","year":"1995","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ero.2025.05.001_bib0006","first-page":"1058","article-title":"Adult Still\u2019s disease: a multicenter survey of Japanese patients","volume":"17","author":"Ohta","year":"1990","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0007","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","article-title":"Adult Still\u2019s disease: manifestations, disease course, and outcome in 62 patients","volume":"70","author":"Pouchot","year":"1991","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.ero.2025.05.001_bib0008","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ncprheum0510","article-title":"Adult-onset Still\u2019s disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?","volume":"3","author":"Efthimiou","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"11","key":"10.1016\/j.ero.2025.05.001_bib0009","first-page":"758","article-title":"Adult Still\u2019s disease. Part II. Management, outcome, and prognostic factors","volume":"62","author":"Masson","year":"1995","journal-title":"Rev Rhum Engl Ed"},{"issue":"6","key":"10.1016\/j.ero.2025.05.001_bib0010","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3899\/jrheum.170955","article-title":"Macrophage activation syndrome in patients affected by adult-onset Still disease: analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale cohort","volume":"45","author":"Ruscitti","year":"2018","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.ero.2025.05.001_bib0011","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/1744666X.2018.1465821","article-title":"Complications of adult-onset Still\u2019s disease and their management","volume":"14","author":"Mitrovic","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0012","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.berh.2016.08.003","article-title":"MA Gonz\u00e1lez-Gay Adult-onset Still\u2019s disease: advances in the treatment","volume":"30","author":"Casta\u00f1eda","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.ero.2025.05.001_bib0013","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/1744666X.2017.1375853","article-title":"Biologic drugs in adult onset Still\u2019s disease: a systematic review and meta-analysis of observational studies","volume":"13","author":"Ruscitti","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0014","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.semarthrit.2017.06.006","article-title":"Adult onset Still\u2019s disease\u2014the evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)","volume":"47","author":"Junge","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0015","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/ard.2009.108068","article-title":"IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still\u2019s disease","volume":"69","author":"Naumann","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ero.2025.05.001_bib0016","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/ard.2006.066381","article-title":"Anakinra treatment in patients with adult-onset Still\u2019s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial","volume":"66","author":"Kalliolias","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.05.001_bib0017","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2147\/DDDT.S73428","article-title":"Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety","author":"Zhang","year":"2014","journal-title":"Drugs Des Devel Ther."},{"issue":"12","key":"10.1016\/j.ero.2025.05.001_bib0018","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/annrheumdis-2012-201409","article-title":"IL-1 Trap rilonacept in refractory adult onset Still\u2019s disease","volume":"71","author":"Petryna","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0019","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.semarthrit.2012.03.004","article-title":"The use of canakinumab, a novel IL-1\u03b2 long-acting inhibitor, in refractory adult-onset Still\u2019s disease","volume":"42","author":"Kontzias","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ero.2025.05.001_bib0020","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.05.001_bib0021","unstructured":"EULAR task forces [Internet]. Zurich: European Alliance of Associations for Rheumatology (EULAR); [cited 2025 July 02]. Available from: https:\/\/www.eular.org\/eular-task-forces."},{"issue":"7","key":"10.1016\/j.ero.2025.05.001_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.ero.2025.05.001_bib0023","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ero.2025.05.001_bib0024","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/088506660101600307","article-title":"Evidence-based medicine: how to practice and teach EBM, 2nd ed. By David L. Sackett, Sharon E. Straus, W. Scott Richardson, William Rosenberg, and R. Brian Haynes. Churchill Livingstone; 2000","volume":"16","author":"Luckmann","year":"2001","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.ero.2025.05.001_bib0025","unstructured":"Study quality assessment tools [Internet]; Bethesda (MD): National Heart, Lung, and Blood Institute (NHLB); [cited 2025 May 25]. Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"10.1016\/j.ero.2025.05.001_bib0026","unstructured":"Oxford Centre for Evidence-Based Medicine: Levels of Evidence \u2013 March 2009 [Internet] Oxford: Centre for Evidence-Based Medicine; 2009 Jun. [cited 2025 May 25]. Available from: https:\/\/www.cebm.net\/2009\/06\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/."},{"issue":"12","key":"10.1016\/j.ero.2025.05.001_bib0027","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still\u2019s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ero.2025.05.001_bib0028","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","article-title":"Canakinumab for treatment of adult-onset Still\u2019s disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.05.001_bib0029","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fphar.2017.00369","article-title":"Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still\u2019s disease: a multicentre retrospective observational study","volume":"8","author":"Colafrancesco","year":"2017","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.ero.2025.05.001_bib0030","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","article-title":"Tofacitinib in refractory adult-onset Still\u2019s disease: 14 cases from a single centre in China","volume":"79","author":"Hu","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ero.2025.05.001_bib0031","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semarthrit.2020.10.011","article-title":"Outcome of refractory to conventional and\/or biologic treatment adult Still\u2019s disease following canakinumab treatment: countrywide data in 50 patients","volume":"51","author":"Laskari","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ero.2025.05.001_bib0032","article-title":"A pilot study on tocilizumab for treating refractory adult-onset Still\u2019s disease","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ero.2025.05.001_bib0033","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10067-013-2381-5","article-title":"Tocilizumab for the treatment of adult-onset Still\u2019s disease: results from a case series","volume":"33","author":"Cipriani","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.05.001_bib0034","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/acr.20319","article-title":"Tocilizumab in refractory adult Still\u2019s disease: refractory ASD and Tocilizumab","volume":"63","author":"Pu\u00e9chal","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.ero.2025.05.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8054961","article-title":"Real-life data on the efficacy of canakinumab in patients with adult-onset Still\u2019s disease","volume":"2020","author":"Vitale","year":"2020","journal-title":"Mediators Inflamm"},{"issue":"5","key":"10.1016\/j.ero.2025.05.001_bib0036","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/art.10231","article-title":"Etanercept in the treatment of adult patients with Still\u2019s disease","volume":"46","author":"Husni","year":"2002","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1016\/j.ero.2025.05.001_bib0037","article-title":"Efficacy of canakinumab as first-line biologic agent in adult-onset Still\u2019s disease","volume":"21","author":"Cavalli","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.ero.2025.05.001_bib0038","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10067-003-0775-5","article-title":"Successful treatment of refractory adult-onset Still\u2019s disease with infliximab. A prospective, non-comparative series of four patients","volume":"23","author":"Kokkinos","year":"2004","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0039","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3899\/jrheum.130881","article-title":"Tocilizumab in Adult-onset Still\u2019s Disease: the Israeli Experience","volume":"41","author":"Elkayam","year":"2014","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.ero.2025.05.001_bib0040","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/art.38398","article-title":"Efficacy of Tocilizumab in Conventional Treatment-Refractory Adult-Onset Still\u2019s Disease: Multicenter Retrospective Open-Label Study of Thirty-Four Patients: Tocilizumab in AOSD Refractory to Standard Treatment","volume":"66","author":"Ortiz-Sanju\u00e1n","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"39","key":"10.1016\/j.ero.2025.05.001_bib0041","doi-asserted-by":"crossref","first-page":"e1554","DOI":"10.1097\/MD.0000000000001554","article-title":"Efficacy of anakinra in refractory adult-onset Still\u2019s disease: multicenter study of 41 patients and literature review","volume":"94","author":"Ortiz-Sanju\u00e1n","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.ero.2025.05.001_bib0042","first-page":"295","article-title":"Intravenous immunoglobulin in adult Still\u2019s disease refractory to non-steroidal anti-inflammatory drugs","volume":"16","author":"Vignes","year":"1998","journal-title":"Clin Exp Rheumatol"},{"issue":"32","key":"10.1016\/j.ero.2025.05.001_bib0043","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016682","article-title":"Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate: a STROBE-compliant article","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.ero.2025.05.001_bib0044","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/art.21061","article-title":"Rapid responses to anakinra in patients with refractory adult-onset Still\u2019s disease","volume":"52","author":"Fitzgerald","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ero.2025.05.001_bib0045","first-page":"1582","article-title":"Cyclosporin A in the treatment of adult onset Still\u2019s disease","volume":"24","author":"Marchesoni","year":"1997","journal-title":"J Rheumatol"},{"issue":"Suppl 3","key":"10.1016\/j.ero.2025.05.001_bib0046","doi-asserted-by":"crossref","first-page":"iii55","DOI":"10.1136\/ard.60.90003.iii55","article-title":"Successful treatment of a small cohort of patients with adult onset of Still\u2019s disease with infliximab: first experiences","volume":"60","author":"Kraetsch","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0047","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.semarthrit.2010.12.006","article-title":"The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients","volume":"41","author":"Colina","year":"2011","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"5","key":"10.1016\/j.ero.2025.05.001_bib0048","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/acr.21901","article-title":"Anakinra in adult-onset Still\u2019s disease: long-term treatment in patients resistant to conventional therapy: long-term efficacy and safety of anakinra in AOSD","volume":"65","author":"Giampietro","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.ero.2025.05.001_bib0049","first-page":"16634","article-title":"Clinical features and prognosis of adult-onset Still\u2019s disease: 75 cases from China","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"6","key":"10.1016\/j.ero.2025.05.001_bib0050","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1111\/1756-185X.12012","article-title":"Adult onset Still\u2019s disease: experience from a tertiary care rheumatology unit","volume":"15","author":"Reddy Munagala","year":"2012","journal-title":"Int J Rheum Dis"},{"issue":"12","key":"10.1016\/j.ero.2025.05.001_bib0051","first-page":"2345","article-title":"Clinical characteristics, treatment, and outcome of adult onset Still\u2019s disease in southern Chinese","volume":"25","author":"Mok","year":"1998","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.05.001_bib0052","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3899\/jrheum.080537","article-title":"The mid-range of the adjusted level of ferritin can predict the chronic course in patients with adult onset Still\u2019s disease","volume":"36","author":"Lee","year":"2009","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.ero.2025.05.001_bib0053","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/RHU.0b013e3181b57199","article-title":"Liver abnormalities in adult onset Still\u2019s disease: a retrospective study of 77 Chinese patients","volume":"15","author":"Zhu","year":"2009","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.05.001_bib0054","first-page":"47","article-title":"Adult-onset Still\u2019s disease: clinical, serological and therapeutic considerations","volume":"31","author":"Iliou","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.ero.2025.05.001_bib0055","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-onset Still\u2019s disease","volume":"13","author":"Gerfaud-Valentin","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"15","key":"10.1016\/j.ero.2025.05.001_bib0056","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015123","article-title":"Managing adult-onset Still\u2019s disease: the effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study","volume":"98","author":"Ruscitti","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ero.2025.05.001_bib0057","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/s10165-008-0126-0","article-title":"Cyclosporin A treatment for Japanese patients with severe adult-onset Still\u2019s disease","volume":"19","author":"Mitamura","year":"2009","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.ero.2025.05.001_bib0058","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13936","article-title":"Adult-onset still\u2019s disease and treatment results with tocilizumab","volume":"75","author":"K\u0131r","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.ero.2025.05.001_bib0059","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/14397595.2014.974881","article-title":"Nationwide epidemiological survey of 169 patients with adult Still\u2019s disease in Japan","volume":"25","author":"Asanuma","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.05.001_bib0060","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13054-018-2012-2","article-title":"Diagnostic and management of life-threatening adult-onset Still disease: a French nationwide multicenter study and systematic literature review","volume":"22","author":"N\u00e9el","year":"2018","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.ero.2025.05.001_bib0061","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/03009742.2014.992949","article-title":"Efficacy and safety of biological agents in adult-onset Still\u2019s disease","volume":"44","author":"Cavalli","year":"2015","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"10.1016\/j.ero.2025.05.001_bib0062","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s10067-016-3308-8","article-title":"Adult-onset Still\u2019s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients","volume":"35","author":"Sfriso","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.ero.2025.05.001_bib0063","first-page":"11","article-title":"Calcineurin inhibitors for adult-onset Still\u2019s disease: a multicentre retrospective cohort study","volume":"127","author":"Nakamura","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.ero.2025.05.001_bib0064","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/14397595.2014.933997","article-title":"Usefulness of tacrolimus for refractory adult-onset still\u2019s disease: report of six cases","volume":"26","author":"Nakamura","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.ero.2025.05.001_bib0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/14397595.2014.973659","article-title":"The effect of tocilizumab on preventing relapses in adult-onset Still\u2019s disease: a retrospective, single-center study","volume":"25","author":"Nishina","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0066","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MD.0000000000000021","article-title":"Adult-onset Still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients","volume":"93","author":"Gerfaud-Valentin","year":"2014","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0067","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","article-title":"Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still\u2019s disease: an observational study of 20 cases","volume":"64","author":"Fautrel","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0068","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/14397595.2014.899178","article-title":"Successful tocilizumab therapy in seven patients with refractory adult-onset Still\u2019s disease","volume":"26","author":"Bannai","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"4","key":"10.1016\/j.ero.2025.05.001_bib0069","first-page":"1010","article-title":"Biomarkers for disease flare in patients with adult-onset Still\u2019s disease undergoing treatment with tocilizumab","volume":"59","author":"Yamada","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0070","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/ard.56.2.144","article-title":"Methotrexate treatment in patients with adult onset Still\u2019s disease\u2014retrospective study of 13 Japanese cases","volume":"56","author":"Fujii","year":"1997","journal-title":"Ann Rheum. Dis."},{"issue":"3","key":"10.1016\/j.ero.2025.05.001_bib0071","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerre","year":"2007","journal-title":"Ann Rheum. Dis."},{"key":"10.1016\/j.ero.2025.05.001_bib0072","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fphar.2019.00296","article-title":"Long-term retention rate of anakinra in adult onset Still\u2019s disease and predictive factors for treatment response","volume":"10","author":"Vitale","year":"2019","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.ero.2025.05.001_bib0073","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.semarthrit.2007.04.002","article-title":"Anakinra in patients with treatment-resistant adult-onset Still\u2019s disease: four case reports with serial cytokine measurements and a review of the literature","volume":"37","author":"K\u00f6tter","year":"2007","journal-title":"Semin Arthritis Rheum"},{"issue":"6 Suppl 102","key":"10.1016\/j.ero.2025.05.001_bib0074","first-page":"S64","article-title":"Efficacy of tocilizumab therapy in Korean patients with adult-onset Still\u2019s disease: a multicentre retrospective study of 22 cases","volume":"34","author":"Song","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.ero.2025.05.001_bib0075","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00296-009-1277-9","article-title":"Clarithromycin in adult-onset Still\u2019s disease: a study of 6 cases","volume":"30","author":"Saviola","year":"2010","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.ero.2025.05.001_bib0076","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study","volume":"39","author":"Nordstr\u00f6m","year":"2012","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.ero.2025.05.001_bib0077","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/ard.59.5.347","article-title":"Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still\u2019s disease","volume":"59","author":"Vignes","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ero.2025.05.001_bib0078","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1038\/s41598-017-04086-w","article-title":"Upregulation of circulating microRNA-134 in adult-onset Still\u2019s disease and its use as potential biomarker","volume":"7","author":"Liao","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0079","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10067-020-05266-2","article-title":"Systemic immune-inflammation index combined with ferritin can serve as a reliable assessment score for adult-onset Still\u2019s disease","volume":"40","author":"Kim","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ero.2025.05.001_bib0080","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3389\/fphar.2019.00918","article-title":"Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset Still disease","volume":"10","author":"Sota","year":"2019","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.ero.2025.05.001_bib0081","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.3899\/jrheum.100247","article-title":"Clinical manifestations but not cytokine profiles differentiate adult-onset Still\u2019s disease and sepsis","volume":"37","author":"Rau","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ero.2025.05.001_bib0082","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13023-015-0228-7","article-title":"Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey","volume":"10","author":"Rossi-Semerano","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.ero.2025.05.001_bib0083","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s10067-010-1516-1","article-title":"Clinical features and prognosis in adult-onset Still\u2019s disease: a study of 104 cases","volume":"29","author":"Kong","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.ero.2025.05.001_bib0084","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/03009740600709816","article-title":"Long-term follow-up of patients with adult-onset Still\u2019s disease","volume":"35","author":"Akritidis","year":"2006","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"10.1016\/j.ero.2025.05.001_bib0085","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s10067-006-0440-x","article-title":"Ten years of clinical experience with adult onset Still\u2019s disease: is the outcome improving?","volume":"26","author":"Uppal","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ero.2025.05.001_bib0086","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaut.2016.02.010","article-title":"Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still\u2019s disease: data from a large multicenter cohort","volume":"69","author":"Kalyoncu","year":"2016","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.ero.2025.05.001_bib0087","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3109\/s10165-011-0569-6","article-title":"Therapeutic response of patients with adult Still\u2019s disease to biologic agents: multicenter results in Japan","volume":"22","author":"Suematsu","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ero.2025.05.001_bib0088","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.0 [Internet] (updated July, 2019","year":"2019"},{"issue":"3","key":"10.1016\/j.ero.2025.05.001_bib0089","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/19439342.2012.711342","article-title":"The benefits and challenges of using systematic reviews in international development research","volume":"4","author":"Mallett","year":"2012","journal-title":"J Dev Eff"},{"issue":"5","key":"10.1016\/j.ero.2025.05.001_bib0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrrheum.2013.14","article-title":"Mechanistic biomarkers for clinical decision making in rheumatic diseases","volume":"9","author":"Robinson","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.ero.2025.05.001_bib0091","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s40265-018-0956-9","article-title":"Adult-onset Still\u2019s disease: molecular pathophysiology and therapeutic advances","volume":"78","author":"Sfriso","year":"2018","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ero.2025.05.001_bib0092","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.berh.2008.08.006","article-title":"Adult-onset Still disease","volume":"22","author":"Fautrel","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0093","first-page":"322","article-title":"Diagnostic value of ferritin and glycosylated ferritin in adult onset Still\u2019s disease","volume":"28","author":"Fautrel","year":"2001","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.ero.2025.05.001_bib0094","first-page":"890","article-title":"Serum ferritin and isoferritins are tools for diagnosis of active adult Still\u2019s disease","volume":"21","author":"Van Reeth","year":"1994","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.ero.2025.05.001_bib0095","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/art.11151","article-title":"Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression","volume":"48","author":"Netea","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ero.2025.05.001_bib0096","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cyto.2012.02.006","article-title":"Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6","volume":"58","author":"Shimizu","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.ero.2025.05.001_bib0097","series-title":"The Delphi method: an experimental study of group opinion [Internet]","author":"Dalkey","year":"1969"},{"issue":"7001","key":"10.1016\/j.ero.2025.05.001_bib0098","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/bmj.311.7001.376","article-title":"Qualitative research: consensus methods for medical and health services research","volume":"311","author":"Jones","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.ero.2025.05.001_bib0099","series-title":"The Delphi method: techniques and applications","first-page":"620","author":"Linstone","year":"1975"},{"issue":"3","key":"10.1016\/j.ero.2025.05.001_bib0100","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semarthrit.2019.04.004","article-title":"Racial\/Ethnic variations in morbidity and mortality in adult Onset Still\u2019s disease: an analysis of national dataset","volume":"49","author":"Mehta","year":"2019","journal-title":"Semin Arthritis Rheum"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305070812500031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305070812500031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:21:08Z","timestamp":1790900468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S305070812500031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S305070812500031X"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.05.001","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical, biological, and radiological changes under therapy, and criteria for clinical response and remission in adult-onset Still's disease: a systematic literature review informing the development of the European Alliance of Associations for Rheumatology (EULAR) criteria for assessing disease activity","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}],"article-number":"100017"}}